Publicaciones científicas

What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis

Bronte G(1), Rolfo C(2), Passiglia F(1), Rizzo S(1), Gil-Bazo I(3), Fiorentino E(4), Cajozzo M(5), Van Meerbeeck JP(6), Lequaglie C(7), Santini D(8), Pauwels P(9), Russo A(1).

(1) Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy.
(2) Phase I-Early Clinical Trials Unit, Oncology Department and Multidisciplinary Oncology Center Antwerp (MOCA) Antwerp University Hospital, Edegem, Belgium.
(3) Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
(4) Department of Surgical, Oncological and Oral Sciences, Section of Surgical Oncology, University of Palermo, Palermo, Italy.
(5) Department of Surgical, Oncological and Oral Sciences, Section of Thoracic Surgery, University of Palermo, Palermo, Italy.
(6) Thoracic Oncology, Multidisciplinary Oncology Center Antwerp (MOCA) Antwerp University Hospital, Edegem, Belgium.
(7) Department of Thoracic Surgery, I.R.C.C.S.-C.R.O.B. Basilicata Regional Cancer Institute, Rionero in Vulture, Italy.
(8) Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy.
(9) Molecular Pathology Unit, Pathology Department and Multidisciplinary Oncology Center Antwerp (MOCA) Antwerp University Hospital, Edegem, Belgium.

Revista: Critical Reviews in Oncology/Hematology

Fecha: 11/04/2015

Oncología Médica

BACKGROUND:
Randomized phase III trials showed interesting, but conflicting results, regarding the treatment of NSCLC, PS2 population. This meta-analysis aims to review all randomized trials comparing platinum-based doublets and single-agents in NSCLC PS2 patients.

MATERIALS AND METHODS:
Data from all published randomized trials, comparing efficacy and safety of platinum-based doublets to single agents in untreated NSCLC, PS2 patients, were collected. Pooled ORs were calculated for the 1-year Survival-Rate (1y-SR), Overall Response Rate (ORR), and grade 3-4 (G3-4) hematologic toxicities.

RESULTS:
Six eligible trials (741 patients) were selected. Pooled analysis showed a significant improvement in ORR (OR: 3.243; 95% CI: 1.883-5.583) and 1y-SR (OR: 1.743; 95% CI: 1.203-2.525) in favor of platinum-based doublets. G3-4 hematological toxicities were also more frequent in this group.

CONCLUSION:
This meta-analysis suggests that platinum-combination regimens are superior to singleagent both in terms of ORR and survival-rate with increase of severe hematological toxicities.

CITA DEL ARTÍCULO  Crit Rev Oncol Hematol. 2015 Apr 11. pii: S1040-8428(15)00066-9. doi: 10.1016/j.critrevonc.2015.03.010.

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra